98%
921
2 minutes
20
Drug-induced liver injury (DILI) continues to be one of the leading causes of drug attrition during clinical trials, as well as the number one cause of post-market drug withdrawal due to the limited predictive accuracy of preclinical animals and conventional in vitro models. In this study, the NANOSTACKS platform was introduced as a novel in vitro tool to build in vivo-relevant organ models for predicting drug responses. In particular, hepatic models, including monocultures of primary human hepatocytes (PHH), tricultures of PHH, human stellate cells (HSC), and human liver endothelial cells (LECs), and tetracultures of PHH, HSC, LECs, and human Kupffer cells (KC) were developed under static and orbital-induced mixing flow conditions. All hepatic models were characterised by assessing albumin, urea, CYP3A4, and ATP production. In addition, the preclinical DILI screening potential of the orbital-induced mixing flow monoculture and triculture models was assessed by testing the hepatotoxicity of zileuton, buspirone, and cyclophosphamide. NANOSTACKS™ represents a promising tool for the development of complex in vitro models.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283536 | PMC |
http://dx.doi.org/10.1007/s44164-025-00089-4 | DOI Listing |
Arch Med Res
September 2025
Department and Graduate Institute of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan. Electronic address:
Background: Atherosclerosis, a leading cause of cardiovascular disease (CVD) mortality worldwide, is characterized by dysregulated lipid metabolism and unresolved inflammation. Macrophage-derived foam cell formation and apoptosis contribute to plaque formation and vulnerability. Elevated serum galectin-3 (Gal-3) levels are associated with increased CVD risk, and Gal-3 in plaques is strongly associated with macrophages.
View Article and Find Full Text PDFJ Agric Food Chem
September 2025
Laboratory of Food Proteins and Colloids, School of Food Science and Engineering, Guangdong Province Key Laboratory for Green Processing of Natural Products and Product Safety, South China University of Technology, Guangzhou 510640, China.
Soy protein remains a key component of plant-based food development, but its application is challenged by inherent allergenicity. Previous work identified that native amyloid-like protein aggregates in soy 7S globulin that resist gastrointestinal digestion and exhibit pronounced antigenicity. Herein, we demonstrate that protein deamidation significantly enhances proteolysis under an infant gastrointestinal digestion model, leading to ∼80 and 50% reductions in IgG- and IgE-binding capacities, respectively.
View Article and Find Full Text PDFSci Adv
September 2025
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
(phosphatidylserine synthase 1) encodes an enzyme that facilitates production of phosphatidylserine (PS), which mediates a global immunosuppressive signal. Here, based on in vivo CRISPR screen, we identified PTDSS1 as a target to improve anti-PD-1 therapy. Depletion of in tumor cells increased expression of interferon-γ (IFN-γ)-regulated genes, including , , , and , even in the absence of IFN-γ stimulation in vitro.
View Article and Find Full Text PDFSci Adv
September 2025
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing, China.
Regulatory T cells are essential for immune homeostasis. While CD4 T cells are well characterized, CD8 T cells remain less understood and are primarily observed in pathological or experimental contexts. Here, we identify a naturally occurring CD8 regulatory precursor T cell at the steady state, defined by a CD8HLA-DRCD27 phenotype and a transcriptome resembling CD4 T cells.
View Article and Find Full Text PDFSci Transl Med
September 2025
Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
IFN-β, a type I interferon, has been used as a first-line therapy for patients with multiple sclerosis (MS) for more than 30 years; however, the cellular and molecular basis of its therapeutic efficacy remains unclear. Here, we first used experimental autoimmune encephalomyelitis (EAE), a mouse model for MS, to show that the therapeutic effects of IFN-β were associated with a down-regulation of microRNA-21 (miR-21) and pathogenic T17 (pT17) cells. In vitro experiments demonstrated that genetic knockout of miR-21 directly inhibited pathogenic T17 cell differentiation.
View Article and Find Full Text PDF